Compare CVU & KLRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVU | KLRS |
|---|---|---|
| Founded | 1980 | 2019 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 44.5M | 46.0M |
| IPO Year | N/A | N/A |
| Metric | CVU | KLRS |
|---|---|---|
| Price | $2.89 | $5.49 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $21.50 |
| AVG Volume (30 Days) | ★ 205.0K | 160.4K |
| Earning Date | 11-14-2025 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $71,616,326.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.02 | $2.14 |
| 52 Week High | $5.85 | $12.90 |
| Indicator | CVU | KLRS |
|---|---|---|
| Relative Strength Index (RSI) | 62.87 | 48.34 |
| Support Level | $2.69 | $5.10 |
| Resistance Level | $2.89 | $7.07 |
| Average True Range (ATR) | 0.19 | 0.68 |
| MACD | 0.05 | -0.09 |
| Stochastic Oscillator | 88.54 | 29.52 |
CPI Aerostructures Inc is engaged in the manufacturing of structural aircraft parts for fixed-wing aircraft and helicopters in both the commercial and defense markets in the United States. It also provides engineering, program management, supply chain management and kitting, and Maintenance Repair and Overhaul (MRO) services. CPI also acts as a subcontractor to prime aircraft manufacturers in the production of commercial aircraft parts. CPI Aero supplies the E-2D Advanced Hawkeye surveillance aircraft, the A-10 Thunderbolt attack jet, the Gulfstream G650, the UH-60 BLACK HAWK helicopter, and the S-92 helicopter, and others.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor (VEGF) drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.